WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Abata Therapeutics, a clinical-stage biotech company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory ...

WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe ...

WATERTOWN, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Abata Therapeutics, a company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory diseases, today announced it ...

Abata Therapeutics has launched with $95 million in series A funding to take cell therapy into a new realm: the treatment of multiple sclerosis. The investment comes primarily from Third Rock Ventures ...

After three and a half years of incubation at Third Rock Ventures, Abata Therapeutics is ready to unveil itself with $95 million in series A funds to bring cell therapies into the clinic for ...

Abata Therapeutics is a biotechnology company that develops and commercializes gene therapies for the treatment of rare genetic diseases. The company's lead product candidate is a gene therapy for the ...

BOSTON--(BUSINESS WIRE)--Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and ...

Abata Therapeutics Inc. announced it has received an equity investment from Bristol Myers Squibb to support the development of its Treg cell therapy products. Their investment supports Abata's ...

The Series A financing announced Wednesday was led by Third Rock Ventures. Boston-based Abata is developing therapies from regulatory T cells (Tregs), the counterpart to T cells. While T cells attack ...